Drug Profile

HMI 103

Alternative Names: HMI-103

Latest Information Update: 27 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Beckman Research Institute
Developer Q32 Bio
Class Gene therapies
Mechanism of Action Gene transference; Phenylalanine ammonia lyase replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Phenylketonuria
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Phenylketonuria

Most Recent Events

25 Mar 2024 Q32 Bio has merged with Homology Medicines to form Q32 Bio
14 Sep 2023 Homology Medicines terminates a phase I pheEDIT trial for Phenylketonuria in USA (IV) as the Company discontinued the development of this program (NCT05222178)
27 Jul 2023 HMI 103 is available for licensing as of 27 Jul 2023. https://www.homologymedicines.com/pipeline/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com